Rain Oncology Inc. Net Income
Rain Oncology Inc. reported Net Income of -$7.03 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2023-11-09
- Rain Oncology Inc. net income (loss) attributable to parent for the quarter ending 2023-09-30 was -$7.03M.
- Rain Oncology Inc. net income (loss) attributable to parent for the quarter ending 2023-06-30 was -$22.06M.
- Rain Oncology Inc. net income (loss) attributable to parent for the quarter ending 2023-03-31 was -$20.48M.
- Rain Oncology Inc. net income (loss) attributable to parent for the quarter ending 2022-12-31 was -$22.68M.
- Rain Oncology Inc. net income (loss) attributable to parent for fiscal 2022 was -$75.72M.
- Rain Oncology Inc. net income (loss) attributable to parent for fiscal 2021 was -$51.39M.
- Rain Oncology Inc. net income (loss) attributable to parent for fiscal 2020 was -$21.08M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$7.03M 10-Q · filed 2023-11-09 | -$29.10M derived: sum of 2 quarters · filed 2023-11-09 | -$49.58M 10-Q · filed 2023-11-09 | -$72.26M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | -$22.06M 10-Q · filed 2023-11-09 | -$42.55M 10-Q · filed 2023-08-10 | -$65.23M derived: sum of 3 quarters · filed 2023-11-09 | -$83.27M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | -$20.48M 10-Q · filed 2023-11-09 | -$43.16M derived: sum of 2 quarters · filed 2023-11-09 | -$61.20M derived: sum of 3 quarters · filed 2023-11-09 | -$78.81M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | -$22.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$40.72M derived: sum of 2 quarters · filed 2023-11-09 | -$58.33M derived: sum of 3 quarters · filed 2023-11-09 | -$75.72M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$18.04M 10-Q · filed 2023-11-09 | -$35.65M derived: sum of 2 quarters · filed 2023-11-09 | -$53.05M 10-Q · filed 2023-11-09 | -$71.03M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$17.61M 10-Q · filed 2023-11-09 | -$35.01M 10-Q · filed 2023-08-10 | -$52.99M derived: sum of 3 quarters · filed 2023-11-09 | -$71.42M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-03-31 | -$17.39M 10-Q · filed 2023-11-09 | -$35.38M derived: sum of 2 quarters · filed 2023-11-09 | -$53.80M derived: sum of 3 quarters · filed 2023-11-09 | -$61.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2021-12-31 | -$17.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$36.41M derived: sum of 2 quarters · filed 2023-03-09 | -$44.59M derived: sum of 3 quarters · filed 2023-03-09 | -$51.39M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$18.43M 10-Q · filed 2022-11-10 | -$26.61M derived: sum of 2 quarters · filed 2022-11-10 | -$33.41M 10-Q · filed 2022-11-10 | -$38.85M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$8.18M 10-Q · filed 2022-11-10 | -$14.98M 10-Q · filed 2022-08-04 | -$20.43M derived: sum of 3 quarters · filed 2022-11-10 | -$30.87M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | -$6.80M 10-Q · filed 2022-11-10 | -$12.24M derived: sum of 2 quarters · filed 2022-11-10 | -$22.69M derived: sum of 3 quarters · filed 2022-11-10 | -$25.31M derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | -$5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$15.89M derived: sum of 2 quarters · filed 2022-03-03 | -$18.51M derived: sum of 3 quarters · filed 2022-03-03 | -$21.08M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$10.45M 10-Q · filed 2021-11-10 | -$13.07M derived: sum of 2 quarters · filed 2021-11-10 | -$15.64M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.62M 10-Q · filed 2021-11-10 | -$5.19M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$2.57M 10-Q · filed 2021-11-10 |